Literature DB >> 9488788

Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis.

C Nelson-Piercy1.   

Abstract

Heparin is the commonest mode of thromboprophylaxis used in pregnancy. It does not cross the placenta but has potential adverse effects on the mother, of which the most important is heparin-induced osteoporosis. The hazards of heparin, including bleeding, skin reactions, heparin-induced thrombocytopenia and osteoporosis are discussed and the relevant literature reviewed. Low-molecular-weight heparins have certain advantages over standard unfractionated heparins, especially in obstetrics. Their longer half-life and increased bioavailability enable once-daily injections, making them more convenient and acceptable. They are as effective as standard heparin but have a theoretically more favourable side-effect profile, providing less anticoagulant relative to antithrombotic activity. Current evidence suggests a lower incidence of heparin-induced thrombocytopenia. A reduced risk of osteoporosis is suggested but not yet proven. Although thrombo-embolism is currently the leading cause of maternal mortality in the UK, antenatal heparin prophylaxis is not given to all women with previous thrombo-embolism because of continued fears concerning heparin-induced osteoporosis. A protocol is presented with guidelines for different levels of obstetric prophylaxis depending on the perceived level of risk.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9488788     DOI: 10.1016/s0950-3552(97)80024-7

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  10 in total

1.  Use of osteoporosis medications in older nursing facility residents.

Authors:  Rollin M Wright
Journal:  J Am Med Dir Assoc       Date:  2007-08-13       Impact factor: 4.669

2.  Adherence to a guideline for coumarins in pregnancy.

Authors:  Dieneke van Driel; Judit Wesseling; Kirsten ter Huurne; Lya M Geven-Boere; Frits R Rosendaal; Eveline van der Veer; Lolkje T W de Jong-van den Berg
Journal:  Pharm World Sci       Date:  2004-10

Review 3.  Low molecular weight heparins: a guide to their optimum use in pregnancy.

Authors:  Pierre Laurent; Guy-Vincent Dussarat; Jacques Bonal; Christophe Jego; Philippe Talard; Christian Bouchiat; Gilles Cellarier
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Molecular dynamics simulations of aptamer-binding reveal generalized allostery in thrombin.

Authors:  Jiajie Xiao; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2016-11-29

5.  Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.

Authors:  Cunji Gao; Brian Boylan; Juan Fang; David A Wilcox; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

Review 6.  Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.

Authors:  Rebecca Tooher; Simon Gates; Therese Dowswell; Lucy-Jane Davis
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

7.  Venous thromboembolism in pregnancy.

Authors:  Marcelo P Villa-Forte Gomes
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

Review 8.  Anticoagulants in pregnancy.

Authors:  Ian A Greer
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

9.  Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.

Authors:  Philippa Middleton; Emily Shepherd; Judith C Gomersall
Journal:  Cochrane Database Syst Rev       Date:  2021-03-29

Review 10.  Anticoagulants and Osteoporosis.

Authors:  Salvatore Santo Signorelli; Salvatore Scuto; Elisa Marino; Michele Giusti; Anastasia Xourafa; Agostino Gaudio
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.